Drugs / CT7001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03363893 | Nov 2017 → Dec 2022 | high grade malignant neoplasm | Carrick Therapeutics Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-10 | Carrick Therapeutics Limited | Results Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer carricktherapeutics.com ↗
These Phase 2 trial results show that samuraciclib in combination with fulvestrant provided a very notable and clinically meaningful benefit in a broad patient population with HR positive, HER2 negative metastatic breast cancer whose disease progressed following treatment with a CDK4/6 inhibitor. |
| 2025-05-15 | Carrick Therapeutics Limited | Results Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer carricktherapeutics.com ↗
The analysis indicated that study participants with no evidence of a deleterious mutation in the TP53 gene in circulating tumor DNA at baseline or separately, without liver metastases at baseline, experienced extended durations of progression-free survival. |
| 2021-12-09 | Carrick Therapeutics Limited | Results Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium carricktherapeutics.com ↗
Samuraciclib in combination with fulvestrant in the post CDK4/6 setting has demonstrated a median mPFS of 32 weeks. |
| 2021-09-16 | Carrick Therapeutics Limited | Results Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021 carricktherapeutics.com ↗
Data presented from a Phase 2a study of samuraciclib in combination with fulvestrant in women with hormone receptor positive (HR+), HER2- advanced breast cancer (BC) previously treated with a CDK4/6 inhibitor (abstract: 1346 (265P)) demonstrated clinical activity and tolerability that supports further clinical development of the combination. |
| 2021-08-16 | Carrick Therapeutics Limited | Regulatory Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer carricktherapeutics.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT7001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03363893 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |
| Route | Oral | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |